Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma


You May Also Like

OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference

During JP Morgan Healthcare ConferenceSan Francisco, January 7-9, 2019 NANTES, France, Jan. 03, 2019 ...

Novartis successfully completes acquisition of Endocyte

Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant ...